Biogen Tysabri Contract: Anti-T cell therapy for Multiple System Atrophy

Project: Research project

Project Details

Description

Biogen Tysabri Contract: Anti-T cell therapy for Multiple System Atrophy Biogen Tysabri Contract: Anti-T cell therapy for Multiple System Atrophy
StatusActive
Effective start/end date4/18/226/30/22

Funding

  • INDUSTRY: Domestic Company: $89,759.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.